Search

Your search keyword '"Moretto, Roberto"' showing total 7 results
Start Over Author "Moretto, Roberto" Publisher american society of clinical oncology
7 results on '"Moretto, Roberto"'

1. Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.

Author

Antoniotti, Carlotta, Rossini, Daniele, Pietrantonio, Filippo, Salvatore, Lisa, Lonardi, Sara, Tamberi, Stefano, Marmorino, Federica, Moretto, Roberto, Prisciandaro, Michele, Tamburini, Emiliano, Tortora, Giampaolo, Passardi, Alessandro, Bergamo, Francesca, Raimondi, Alessandra, Ritorto, Giuliana, Borelli, Beatrice, Conca, Veronica, Ugolini, Clara, Aprile, Giuseppe, and Antonuzzo, Lorenzo

Published
2024
Full Text
View/download PDF

2. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E -Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy.

Author

Moretto, Roberto, Germani, Marco Maria, Ros, Javier, Daniel, Francesca, Ghelardi, Filippo, Vetere, Guglielmo, Giordano, Mirella, Toledo, Rodrigo De Almeida, Bergamo, Francesca, Randon, Giovanni, Elez, Elena, Lonardi, Sara, Pietrantonio, Filippo, Vignali, Paola, Rossini, Daniele, Matito, Judit, Ugolini, Clara, Fontanini, Gabriella, Masi, Gianluca, and Cremolini, Chiara

Subjects
*DNA mismatch repair, *COLORECTAL cancer, *METASTASIS, *MICROSATELLITE repeats, *HEREDITARY nonpolyposis colorectal cancer, *CANCER chemotherapy, *PROGRESSION-free survival
Abstract

2nd-line target therapy outperforms chemotherapy in patients with BRAFV600E-mut mCRC regardless of RNF43 status. PURPOSE: Target therapy (TT) with encorafenib plus cetuximab is a standard option in patients with BRAFV600E -mutated (mut) pretreated metastatic colorectal cancer (mCRC). Recently, mutations in RNF43 , encoding a negative regulator of the WNT pathway, were associated with longer progression-free survival (PFS) and overall survival (OS) in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) BRAFV600E -mut mCRC treated with TT. Here, we explored the effect of RNF43 mutations on the efficacy of second-line TT versus standard chemotherapy (CT). METHODS: A retrospective cohort of patients with pMMR/MSS BRAFV600E -mut tumors, available RNF43 mutational status, and treated with second-line TT or oxaliplatin- and/or irinotecan-based CT was analyzed. RESULTS: One hundred thirty-two patients with pMMR/MSS BRAFV600E -mut mCRC were included. RNF43 was found mut in 34 (26%) cases. Among RNF43 mutants, TT was associated with longer PFS (7.7 v 3.0 months; P =.002) and higher overall response rate (ORR; 45% v 0%; P =.009) compared with CT. Conversely, among RNF43 wild-type (wt) patients, only a trend for longer PFS (4.5 v 3.7 months; P =.064) favoring TT, with no differences in ORR (P =.14), was observed. After excluding 36 patients receiving TT in third line or beyond, a longer OS (19.4 v 10.1 months; P =.022) and a numerically OS advantage (10.6 v 6.6 months; P =.068) were reported for TT both in the RNF43 -mut and in the RNF43 wt groups. However, no interaction effect was reported between RNF43 mutational status and treatment in ORR (P interaction =.96), PFS (P interaction =.13), and OS (P interaction =.44). CONCLUSION: Patients with pMMR/MSS BRAFV600E -mut mCRC achieve benefit from TT versus CT independently of RNF43 mutational status, although a higher magnitude of benefit from TT is observed in RNF43 -mut tumors. These findings deserve confirmation in concluded and ongoing randomized trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study...

Author

Rossini, Daniele, Antoniotti, Carlotta, Lonardi, Sara, Pietrantonio, Filippo, Moretto, Roberto, Antonuzzo, Lorenzo, Boccaccino, Alessandra, Morano, Federica, Brugia, Marco, Pozzo, Carmelo, Marmorino, Federica, Bergamo, Francesca, Tamburini, Emiliano, Passardi, Alessandro, Randon, Giovanni, Murgioni, Sabina, Borelli, Beatrice, Buonadonna, Angela, Giordano, Mirella, and Fontanini, Gabriella

Published
2022
Full Text
View/download PDF

4. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.

Author

Rossini, Daniele, Antoniotti, Carlotta, Lonardi, Sara, Pietrantonio, Filippo, Moretto, Roberto, Antonuzzo, Lorenzo, Boccaccino, Alessandra, Morano, Federica, Brugia, Marco, Pozzo, Carmelo, Marmorino, Federica, Bergamo, Francesca, Tamburini, Emiliano, Passardi, Alessandro, Randon, Giovanni, Murgioni, Sabina, Borelli, Beatrice, Buonadonna, Angela, Giordano, Mirella, and Fontanini, Gabriella

Published
2022
Full Text
View/download PDF

5. Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).

Author

Carullo, Martina, Germani, Marco Maria, Moretto, Roberto, Conca, Veronica, Minelli, Alessandro, Giordano, Mirella, Bruno, Rossella, Prisciandaro, Michele, Lonardi, Sara, Bensi, Maria, Tonini, Giuseppe, Palladino, Maria Angela, Ramundo, Matteo, Tamberi, Stefano, Antoniotti, Carlotta, Rossini, Daniele, Ugolini, Clara, Marmorino, Federica, Fontanini, Gabriella, and Cremolini, Chiara

Published
2023
Full Text
View/download PDF

6. Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT).

Author

Germani, Marco Maria, Moretto, Roberto, Ros Montañá, Javier, Intini, Rossana, Ghelardi, Filippo, Vetere, Guglielmo, Toledo, Rodrigo De Almeida, Bergamo, Francesca, Randon, Giovanni, Elez, Elena, Lonardi, Sara, Oldani, Simone, Giordano, Mirella, Rossini, Daniele, Ferrari Bravo, Walter, Ricagno, Gianmarco, Vignali, Paola, Ugolini, Clara, Fontanini, Gabriella, and Cremolini, Chiara

Published
2023
Full Text
View/download PDF

7. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.

Author

Antoniotti, Carlotta, Rossini, Daniele, Pietrantonio, Filippo, Salvatore, Lisa, Marmorino, Federica, Ambrosini, Margherita, Lonardi, Sara, Bensi, Maria, Moretto, Roberto, Tamberi, Stefano, Toma, Ilaria, Passardi, Alessandro, De Grandis, Maria Caterina, Conca, Veronica, Palermo, Federica, Cappetta, Alessandro, Catteau, Aurelie, Boni, Luca, Galon, Jérôme, and Cremolini, Chiara

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results